Contrast
PreclinicalSmall molecule
Contrast is one of 43 small molecule programs targeting Nephropathy. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Theo-Dur
PfizerApproved
Rituxan
RocheApproved
Crestor
AstraZenecaApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Micardis
Boehringer IngelheimApproved
Atacand
IIstituto Clinico Humanitas
Approved
Livalo
MMedicure
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart1 trial
Whole-Heart Myocardial Blood Flow Quantification Using MRI
Unknown status·—··NCT03064295·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Contrast. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University